Brief: Immutep Announces Initiation Of Phase II/III Trial For Eftilagimod Alpha Plus Paclitaxel
14/03/2023 13:15
March 14 (Reuters) - Immutep Ltd IMM.AX :
* IMMUTEP ANNOUNCES INITIATION OF PHASE II/III TRIAL FOR
EFTILAGIMOD ALPHA PLUS PACLITAXEL IN METASTATIC BREAST CANCER
* IMMUTEP LTD - APPROVAL FOR STUDY START RECEIVED IN US AND
IRB
APPROVAL IN SPAIN, WITH MORE COUNTRIES TO FOLLOW SHORTLY
* IMMUTEP LTD - FIRST PATIENT EXPECTED TO BE ENROLLED IN
EARLY Q2
CY2023
* IMMUTEP LTD - COMPANY'S EXPECTED CASH RUNWAY TO END OF 1ST
HALF
OF CALENDAR YEAR 2024
Source text for Eikon: ID:nGNXbbl9DF
Further company coverage: IMM.AX
((Reuters.Briefs@thomsonreuters.com;))